Annexin 5 inhibits thyrotropin releasing hormone (TRH) stimulated prolactin release in the primary culture of rat anterior pituitary cells.

Annexin 5, a novel calcium-phospholipid binding protein, is thought to be involved in hormone secretion by the anterior pituitary gland. Gonadotropin releasing hormone stimulates annexin 5 synthesis, which, in turn, enhances gonadotoropin secretion. On the other hand, annexin 5 was shown to inhibit prolactin release in vitro. To understand the nature of the opposing effects of annexin 5 on these two major pituitary hormones, the present study examines the inhibitory effect of annexin 5 on prolactin release in relation to thyrotropin stimulating hormone (TRH) using primary cultures of anterior pituitary cells of adult female rats. While recombinant rat annexin 5 was found to have little effect on basal prolactin release, it significantly inhibited TRH-stimulated prolactin release. Addition of specific anti-annexin 5 serum to the culture increased basal prolactin release in a concentration dependent manner, and no further increase in prolactin release was observed following application of TRH in the presence of anti-annexin 5. The enhanced basal prolactin release induced by anti-annexin 5 was reversed by the simultaneous administration of indomethacin, an inhibitor of cyclooxygenase. These results demonstrate that endogenous pituitary annexin 5 exerts an inhibitory effect on prolactin release and suggest that this is attained by suppression of eicosanoid synthesis in vitro.

Prolactin inhibits annexin 5 expression and apoptosis in the corpus luteum of pseudopregnant rats: involvement of local gonadotropin-releasing hormone.

We investigated a specific relationship between the expression of annexin 5 and prolactin in the corpus luteum of pseudopregnant rats, with particular interest in GnRH and apoptosis of luteal cells. The expression of ovarian annexin 5 mRNA was significantly decreased at mid-pseudopregnancy and recovered at the end, whereas it remained low on the corresponding day of pregnancy. The dopamine agonist CB-154, administered at mid-pseudopregnancy (d 5), increased ovarian annexin 5 mRNA, whereas prolactin, given daily for 3 d to cycling rats, decreased it. An immunocytochemical study also showed that annexin 5 increased in the corpus luteum on d 6 and 7 of pseudopregnancy after treatment with CB-154 on d 5. The distribution of annexin 5-positive cells was not uniform in the corpus luteum and matched that of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL)-positive cells. Because GnRH stimulates annexin 5 mRNA expression in the gonadotropes, involvement of the GnRH receptor was examined. Local administration of a GnRH antagonist, Cetrorelix, to hemilateral ovarian bursa of pseudopregnant rats simultaneously receiving CB-154 abrogated both the expression of annexin 5 and the TUNEL reaction. The present results clearly demonstrate that prolactin decreases annexin 5 mRNA in the luteal cells during pseudopregnancy. Prolactin is suggested to suppress the local action of GnRH, which stimulates annexin 5 synthesis and apoptosis of functional luteal cells during pseudopregnancy.

Adrenal influence on the persistence of pseudopregnancy in rats.

The effect of adrenalectomy on the duration of pseudopregnancy was investigated in rats. When adrenalectomy was performed three days before cervical stimulation or when it was done on the first day (day 1, day of estrus) or day 2 of pseudopregnancy, the duration of the pseudopregnancy was significantly prolonged (3.0, 2.5 and 1.8 days respectively). This effect of adrenalectomy was not seen when operation was delayed until day 4 of pseudopregnancy. Adrenalectomy on day 2 of pseudopregnancy significantly increased prolactin (PRL) release at the time of the nocturnal PRL surge (5:00) on day 7. When rats were ovariectomized simultaneously with adrenalectomy on day 1, the stimulating effect of adrenalectomy on PRL release was more evident. The effect of active immunization against corticosterone on the continuation of pseudopregnancy was also examined. Neutralization of plasma corticosterone extended the duration of pseudopregnancy and the binding activity of the antiserum positively correlated with the length of continuing diestrus (P < 0.05). These results indicate the negative effect of the adrenal glands, which is probably due to corticosterone, on PRL release in pseudopregnant rats and that the early relief of this inhibition extends the duration of pseudopregnancy.

Gonadotropin-releasing hormone stimulates annexin 5 messenger ribonucleic acid expression in the anterior pituitary cells.

We previously reported that annexin 5 is found specifically in gonadotropes and that the expression is dramatically enhanced after ovariectomy. In the present study, the expression of annexin 5 was examined in the primary culture of rat anterior pituitary cells using semiquantitative RT-PCR to determine if it is under the direct control of gonadotropin-releasing hormone (GnRH). Continuous administration of GnRH analog for 1 h enhanced the expression of both FSH beta subunit and annexin 5 mRNA. The expression of annexin 5 mRNA was also augmented by phorbol 12-myristate 13-acetate but not by forskolin. Administration of recombinant rat annexin 5 to the culture increased LH beta mRNA expression. These data clearly demonstrate that the expression of annexin 5 mRNA is directly controlled by GnRH and suggest that annexin 5 is involved in mediating GnRH action in the pituitary gland.

Annexin 5 messenger ribonucleic acid expression in pituitary gonadotropes is induced by gonadotropin-releasing hormone (GnRH) and modulates GnRH stimulation of gonadotropin release.

Our previous studies on annexin 5, a member of the annexin family of proteins, have shown its expression in the anterior pituitary gland, its preferential distribution in gonadotropes, and its increase after ovariectomy. In the present study, we examined (1) whether annexin 5 is synthesized in gonadotropes, (2) whether its expression is under the control of gonadotropin-releasing hormone (GnRH), and (3) the effect of annexin 5 on gonadotropin release. Large cells, also called castration cells, appeared in anterior pituitary tissue 3 weeks after ovariectomy. These cells have been confirmed to be hyperfunctioning gonadotropes and are easily discriminated from other pituitary cells without immunostaining. Using in situ hybridization with a digoxigenin-labeled ribonucleic acid probe, enhanced expression of annexin 5 messenger ribonucleic acid (mRNA) in these gonadotropes was clearly demonstrated. Northern blot analysis showed an increase in the level of annexin 5 mRNA expression 3 weeks after ovariectomy. It was lessened 3 h after the injection of Cetrorelix (GnRH antagonist, 10 microg i.v.). Administration of a GnRH analog [GnRHa; Des-Gly 10 (Pro9) GnRH ethylamide, 0.2 ml of 2.5 microg/ml saline ten times intraperitoneally at 30-min intervals] significantly increased pituitary annexin 5 mRNA. In primary cultures of anterior pituitary cells, recombinant rat annexin 5 stimulated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release in a dose-dependent manner. Concomitant administration of annexin 5 (1 microg/ml) and GnRHa augmented the LH and FSH release induced by GnRHa. After a 1-hour incubation, cycloheximide (10 microg/ml) apparently inhibited the LH response to GnRHa, while annexin 5 (2 microg/ml) moderated this inhibition. Further, the antisense oligodeoxynucleotide to annexin 5 mRNA blunted the LH response to GnRHa. It is thus concluded that annexin 5 is synthesized in the gonadotropes under the effect of GnRH, and it is suggested that annexin 5 synthesis mediates at least partly GnRH receptor signaling to stimulate gonadotropin secretion.